SUPPLEMENTARY DATA

**Table S1:** Mothers’ indications and infants’ age at start of sampling

|  |  |  |
| --- | --- | --- |
| Mother  number | Mother’s indication | Infant age at start of sampling (months) |
| 1 | Rheumatoid arthritis | 11.5 |
| 2 | Crohn’s disease | 2.6 |
| 3 | Rheumatoid arthritis | 2.0 |
| 4 | Crohn’s disease | 1.6 |
| 5 | Rheumatoid arthritis | 2.2 |
| 6 | Rheumatoid arthritis | 5.8 |
| 7 | Crohn’s disease | 5.0 |
| 8 | Crohn’s disease | 1.8 |
| 9 | Crohn’s disease | 2.3 |
| 10 | Rheumatoid arthritis | 2.3 |
| 11 | Ankylosing spondylitis | 2.0 |
| 12 | Axial spondyloarthritis | 4.1 |
| 13 | Psoriatic arthritis | 2.8 |
| 14 | Psoriatic arthritis | 15.3 |
| 15 | Rheumatoid arthritis | 7.8 |
| 16 | Psoriatic arthritis | 16.8 |
| 17 | Rheumatoid arthritis | 4.0 |

**Table S2:** Concentrations of total PEG (μg/mL) in breast milk after administration of CZP dose in mothers

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Mother**  **number** | **Relative time (days)** | | | | | | | | |
| **0** | **2** | **4** | **6** | **8** | **10** | **12** | **14** | **28** |
| **5** | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | - |
| **1** | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | - |
| **9** | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | - |
| **3** | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | - |
| **16** | BLQ | NRa | BLQ | BLQ | BLQ | NRa | BLQ | BLQ | - |
| **11** | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | - |
| **2** | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | - |
| **15** | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | - |
| **10** | BLQ | BLQ | BLQ | NRa | BLQ | BLQ | BLQ | BLQ | - |
| **8** | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | - |
| **12** | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | - |
| **6** | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | - |
| **7** | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | - |
| **4** | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | - |
| **13** | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | - |
| **14** | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | - |
| **17** | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ | BLQ |

Days 0 and 14 are pre-dose for mothers on the CZP 200 mg Q2W dosing regimen.  
Days 0 and 28 are pre-dose for the mother on the CZP 400 mg Q4W dosing regimen.

a134/137 samples had no detectable PEG concentrations. 10% samples were reanalysed for confirmation of results, including the 3 samples where PEG had been detected. On reanalysis, only these 3 revealed a difference from original results with results now being BLQ, and their results were therefore classed as not reportable.

BLQ: below the lower limit of quantification (<0.5μg/mL)

NR: no reportable result